采用内镜筛选和随访评估胶体铋（得乐）治疗十二指肠溃疡的疗效。
Evaluation of colloidal bismuth (De-Nol) in the treatment of duodenal ulcer employing endoscopic selection and follow up.
作者信息
Salmon P R, Brown P, Williams R, Read A E
出版信息
Gut. 1974 Mar;15(3):189-93. doi: 10.1136/gut.15.3.189.
A double-blind, placebo-controlled trial of colloidal bismuth (De-Nol) was performed on 20 patients with active duodenal ulceration employing endoscopic selection and follow up after a treatment period of 28 days. By these means it was shown that healing of ulcers was significant in those patients treated with the active compound. In addition a greater number (9/10) of patients treated with colloidal bismuth showed symptomatic improvement than those receiving placebo (6/10) but this difference did not reach statistical significance. The results of endoscopic and symptomatic assessment of the patients receiving colloidal bismuth were in complete agreement although there was a poor correlation between these results in those receiving the placebo. This supports the results from a previous study that endoscopic assessment of duodenal ulcer healing provides a more objective assessment than do clinical methods.
对20例活动性十二指肠溃疡患者进行了一项关于胶体铋（得乐）的双盲、安慰剂对照试验，采用内镜筛选，并在28天的治疗期后进行随访。通过这些方法表明，使用活性化合物治疗的患者溃疡愈合显著。此外，接受胶体铋治疗的患者中出现症状改善的人数（9/10）比接受安慰剂的患者（6/10）更多，但这种差异未达到统计学显著性。接受胶体铋治疗的患者的内镜和症状评估结果完全一致，尽管接受安慰剂的患者的这些结果之间相关性较差。这支持了先前一项研究的结果，即十二指肠溃疡愈合的内镜评估比临床方法提供了更客观的评估。
Zotero 插件